Internal medicine

Medicine & Life Sciences

1. Activities of Daily Living 9%
2. Anti-Bacterial Agents 20%
3. Antibodies 10%
4. avelumab 34%
5. Axitinib 14%
6. Belgium 57%
7. Biomarkers 15%
8. Blocking Antibodies 9%
9. Brain 11%
10. Brugada Syndrome 17%
11. Cardiac Arrhythmias 10%
12. Catheters 12%
13. Clinical Trials 21%
14. Clinical Trials, Phase I 39%
15. Cohort Studies 12%
16. Continuous Renal Replacement Therapy 30%
17. Coronavirus 60%
18. dabrafenib 35%
19. Delivery of Health Care 11%
20. Dendritic Cells 58%
21. Disease Outbreaks 11%
22. dolutegravir 9%
23. Familial Hypophosphatemic Rickets 9%
24. Fatigue 15%
25. Fever 10%
26. Fluorodeoxyglucose F18 13%
27. Frailty 17%
28. Glioblastoma 28%
29. Glucose 11%
30. Guidelines 12%
31. heparin-binding hemagglutinin 11%
32. HIV 49%
33. HIV Infections 17%
34. HIV-1 37%
35. Hospitalization 12%
36. Human Influenza 9%
37. Immunity 10%
38. Immunotherapy 25%
39. Infections 19%
40. Injections 14%
41. Insulin 11%
42. Ipilimumab 55%
43. Islets of Langerhans 23%
44. Lactams 13%
45. Liver 9%
46. Lymphadenopathy 10%
47. Melanoma 100%
48. Messenger RNA 15%
49. Mitogen-Activated Protein Kinase Kinases 15%
50. Multiple Myeloma 15%
51. Mutation 13%
52. Myeloid Cells 33%
53. Natural Killer T-Cells 9%
54. Neoplasm Metastasis 12%
55. Neoplasms 34%
56. Nivolumab 44%
57. Non-Small Cell Lung Carcinoma 14%
58. Observational Studies 9%
59. Omentum 11%
60. Pancreas 11%
61. Pandemics 18%
62. pembrolizumab 56%
63. Pharmaceutical Preparations 16%
64. Phase II Clinical Trials 24%
65. Pneumonia 9%
66. Population 13%
67. Programmed Cell Death 1 Receptor 9%
68. Quality of Life 9%
69. Recurrence 12%
70. Respiratory Tract Infections 12%
71. Retrospective Studies 14%
72. Rilpivirine 10%
73. RNA 9%
74. Safety 26%
75. SARS Virus 20%
76. Serum 9%
77. Severe Acute Respiratory Syndrome 16%
78. Single-Domain Antibodies 10%
79. Skin 11%
80. Standard of Care 14%
81. Superinfection 18%
82. Survival 22%
83. Survivors 12%
84. Systematic Reviews 18%
85. T-Lymphocytes 21%
86. talimogene laherparepvec 38%
87. Therapeutics 46%
88. Thyroid Gland 16%
89. trametinib 35%
90. Transplants 10%
91. trimix 21%
92. Tsunamis 9%
93. Tumor Burden 19%
94. Type 1 Diabetes Mellitus 25%
95. University Hospitals 12%
96. Vaccination 23%
97. Vaccines 26%
98. Ventilator-Associated Pneumonia 9%
99. Viral Load 10%
100. Viruses 14%